Please check your internet connection and try again.
# Ecospirin (Aspirin, Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of aspirin, a non-steroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, anti-inflammatory, and antiplatelet properties. The enteric coating is designed to release the medication in the small intestine, potentially reducing gastric irritation.
## Primary Indications
* **Cardiovascular prophylaxis:** Prevention of myocardial infarction, stroke, and cardiovascular death in patients with established cardiovascular disease or risk factors.
* **Analgesia and antipyresis:** Mild to moderate pain and fever (though other agents are often preferred for these indications due to gastrointestinal risks).
## Adult Dosing
* **Cardiovascular prophylaxis:**
* **Primary prevention:** Generally not recommended for individuals at low cardiovascular risk. The decision should be individualized based on risk assessment. Doses typically range from 75 mg to 100 mg once daily.
* **Secondary prevention:** 75 mg to 100 mg once daily. Higher doses (e.g., 325 mg) may be used initially after acute cardiovascular events, but lower doses are typically used for long-term maintenance.
* **Pain and fever:** Doses are highly variable and depend on the specific indication. Standard doses range from 325 mg to 650 mg every 4-6 hours as needed. Maximum daily dose generally 4000 mg.
## Pediatric Dosing
Aspirin is generally **contraindicated** in children and adolescents with viral infections (e.g., influenza or varicella) due to the risk of Reye's syndrome. Specific pediatric dosing for approved indications is not well-established or commonly used for widespread indications like pain and fever due to the Reye's syndrome risk.
## Dose Adjustments
No specific dose adjustments are typically required for renal or hepatic impairment in the context of standard cardiovascular prophylaxis doses. However, caution is advised in severe impairment.
## Contraindications
* Hypersensitivity to aspirin, salicylates, or NSAIDs.
* Active peptic ulcer disease.
* Bleeding disorders (e.g., hemophilia, thrombocytopenia).
* Severe renal or hepatic impairment.
* Children and adolescents with viral infections (risk of Reye's syndrome).
* Concurrent use with methotrexate at dosages of 15 mg/week or higher.
## Adverse Effects
* **Gastrointestinal:** Dyspepsia, heartburn, nausea, vomiting, abdominal pain, occult bleeding, peptic ulceration, perforation.
* **Bleeding:** Increased risk of bleeding (e.g., ecchymosis, epistaxis, GI hemorrhage, intracranial hemorrhage).
* **Hypersensitivity reactions:** Bronchospasm (especially in aspirin-sensitive asthmatics), urticaria, angioedema.
* **Other:** Tinnitus, hearing loss (especially with higher doses).
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs and COX-2 inhibitors:** Increased risk of GI toxicity and bleeding.
* **Corticosteroids:** Increased risk of GI toxicity.
* **SSRIs/SNRIs:** Increased risk of bleeding.
* **Uricosuric agents (e.g., probenecid):** Aspirin can decrease the efficacy of uricosuric agents.
* **Methotrexate:** Aspirin can increase methotrexate toxicity.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding (e.g., melena, hematemesis, easy bruising, prolonged bleeding from cuts).
* **GI symptoms:** Assess for abdominal pain, nausea, or dyspepsia.
* **Renal function:** Monitor in patients with risk factors for renal impairment or those on long-term therapy.
## Clinical Pearls
* The enteric coating reduces gastric irritation but does not eliminate the risk of GI bleeding or ulceration, particularly with chronic use.
* Should be taken with a full glass of water. Advise patients not to crush or chew the enteric-coated tablets.
* Discontinue use at least 5-7 days before elective surgery due to its irreversible antiplatelet effect.
* Aspirin's antiplatelet effect is irreversible and lasts for the lifetime of the platelet.
_This information is intended for healthcare professionals and does not substitute for clinical judgment. Always refer to the most current prescribing information and institutional protocols for definitive guidance._
